PCM
SAGE

Palisade Capital Management’s Sage Therapeutics SAGE Stock Holding History

Palisade Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-24,163
Closed -$1.11M – 522
2016
Q3 		$1.11M Sell
24,163
-1,356
-5% -$55.2K 0.04% 402
2016
Q2 		$769K Buy
25,519
+1,522
+6% +$50.8K 0.03% 434
2016
Q1 		$769K Sell
23,997
-588
-2% -$20.7K 0.03% 441
2015
Q4 		$1.43M Sell
24,585
-1,230
-5% -$60.9K 0.05% 380
2015
Q3 		$1.09M Sell
25,815
-45,189
-64% -$2.78M 0.03% 403
2015
Q2 		$5.18M Sell
71,004
-1,793
-2% -$115K 0.13% 264
2015
Q1 		$3.66M Buy
+72,797
New +$3.13M 0.09% 302

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Palisade Capital Management's SAGE Position: Q4 2016 in Review

Palisade Capital Management sold out of Sage Therapeutics (SAGE) in Q4 2016, closing a stake of 24,163 shares — an estimated $1.11M sold.

Palisade Capital Management first reported a position in SAGE in Q1 2015 and held it in 7 quarters. The position peaked at $5.18M in Q2 2015. 166 funds tracked by Wall St. Rank hold SAGE as of Q4 2016.

  • Palisade Capital Management reported no remaining Sage Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Palisade Capital Management sold 24,163 Sage Therapeutics shares in Q4 2016, an estimated $1.11M.
  • Palisade Capital Management first reported a position in Sage Therapeutics in Q1 2015 and held it in 7 quarters.
  • Palisade Capital Management's Sage Therapeutics position peaked at $5.18M in Q2 2015.
  • 166 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2016.

Based on Palisade Capital Management's 13F filing for Q4 2016, filed 31 Jan 2017.